NEW YORK (GenomeWeb) – Illumina and Bristol-Myers Squibb announced after the close of the market Friday that they will collaborate on developing and commercializing companion diagnostics to support BMS' oncology drug pipeline.

The companies plan to develop a diagnostic version of Illumina's TruSight Oncology 500, an assay being developed to target most of the known biomarkers for cancer drugs, including tumor mutation burden and miscrosatellite instability. The panel will run on Illumina's NextSeq 550Dx.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Apr
26
Sponsored by
Thermo Fisher Scientific

In this webinar, the second in the “New Frontiers in Liquid Biopsy Research” series, Luca Quagliata, Senior Consultant in the Molecular Pathology Unit at University Hospital Basel, will share two specific unmet needs within his lab’s liquid biopsy research that led to the eventual evaluation, adoption, and implementation of the latest liquid biopsy Oncomine NGS solutions from Thermo Fisher.

May
01

This webinar will provide an in-depth case study demonstrating how reference standards can be used to develop and validate circulating tumor DNA (ctDNA)-based assays.

May
08

This webinar will discuss a proximity ligation-based method for studying structural variation in formalin-fixed paraffin-embedded (FFPE) tissue.

May
22
Sponsored by
Thermo Fisher Scientific

In this webinar, the third in the “New Frontiers in Liquid Biopsy Research” series, Dr. Liya Xu of the University of Southern California Michelson Center for Convergent Biosciences will discuss her team’s work using liquid biopsy technology for breast cancer research.